Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | F11 | P03951 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | DDO | Q99489 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2947571 | 0.84 | CA12 (0.62) | CA12CA9MAPK1F11CA1 | |
| SCHEMBL18822108 | 0.81 | CA12 (0.55) | CA12CA9MAPK1F11CA1 | |
| SCHEMBL25911641 | 0.78 | CA12 (0.55) | CA12CA9MAPK1F11CA1 | |
| SCHEMBL1119919 | 0.78 | CA12 (0.55) | CA12CA9MAPK1F11CA1 | |
| SCHEMBL30908315 | 0.78 | CA12 (0.55) | CA12CA9MAPK1F11CA1 | |
| SCHEMBL23797291 | 0.78 | CA12 (0.46) | CA12CA9MAPK1F11CA1 | |
| SCHEMBL4553222 | 0.77 | GRIN2D (0.57) | CA12CA9MAPK1F11CA1 | |
| SCHEMBL24220101 | 0.76 | CA12 (0.53) | CA12CA9MAPK1F11CA1 | |
| SCHEMBL17951770 | 0.75 | MAPK1 (0.68) | CA12CA9MAPK1F11CA1 | |
| SCHEMBL12546048 | 0.75 | CA12 (0.51) | CA12CA9MAPK1F11CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2017-10-12 | — | — | US | disclosed |
| US-4710507-A | Quinolone inotropic agents | PFIZER INC. (US) | 1987-12-01 | — | — | US | disclosed |
| CN-85100796-A | The preparation method of qualone derivative | — | 1986-10-01 | — | — | CN | disclosed |
| EP-0148623-A2 | Quinolone inotropic agents | Pfizer Limited (GB) | 1985-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | BRD4, BRPF3, BRD3 | CA12 3674/4885CA9 3195/4885MAPK1 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.